Citracal Quantified Calcium Absorption Superiority Claims Unproven – NAD
This article was originally published in The Tan Sheet
Executive Summary
Quantified claims that Mission Pharmacal's Citracal calcium supplement is better absorbed than calcium carbonate are not supported by the submitted clinical trials and should be discontinued, NAD concludes in an upcoming NAD Case Reports
You may also be interested in...
Caltrate Absorption Comparison With Citracal Needs Clarification – NAD
Promotional claims implying the absorption of Wyeth's Caltrate calcium supplement is equivalent to Mission Pharmacal's Citracal should be modified "to more clearly reflect the conditions under which bioequivalence was demonstrated," the National Advertising Division concludes following a recent inquiry
Citracal ad claims
National Advertising Division of the Council of Better Business Bureaus concludes unqualified marketing claims that Mission Pharmacal's Citracal is "better absorbed than calcium carbonate" should be discontinued. Group also found superior solubility claims made in the absence of superior absorption statements would be supported by the firm's in vitro data if "carefully qualified." Concluded May 5, inquiry was prompted by GlaxoSmithKline, marketer of OsCal supplements with calcium carbonate. NAD's recommendations reflect and confirm January decision by National Advertising Review Board regarding similar Citracal claims and supporting data. That case involved a challenge by Caltrate marketer Wyeth Consumer Healthcare (1"The Tan Sheet" Aug. 5, 2002, p. 7)...
Os-Cal, Citracal Parity Claims Modification Recommended By NAD
GlaxoSmithKline's ad claims that its Os-Cal calcium supplement is absorbed "just as well as" Mission Pharmacal's Citracal may be misleading without "more clearly communicat[ing] the basis of the declared comparison," the National Advertising Division of the Council of Better Business Bureaus concludes in a recently released Case Report